Published in J Virol on December 01, 1992
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol (1993) 1.93
Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc Natl Acad Sci U S A (1994) 1.48
Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol (2000) 1.46
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
In vivo footprinting analysis of constitutive and inducible protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1. J Virol (1993) 1.39
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. J Virol (1994) 1.36
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol (1995) 1.30
Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol (1995) 1.28
Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol (1996) 1.27
Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol (2000) 1.24
Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest (1996) 1.20
Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol (1995) 1.16
Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. J Clin Microbiol (1997) 1.14
Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay. J Clin Microbiol (1995) 1.14
Quantitation of hepatitis C virus genome molecules in plasma samples. J Clin Microbiol (1994) 1.12
Quantitative molecular analysis of virus expression and replication. J Clin Microbiol (2000) 1.11
Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1. J Virol (1996) 1.10
Equine infectious anemia virus is found in tissue macrophages during subclinical infection. J Virol (1998) 1.07
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol (1994) 1.04
Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol (1999) 1.04
Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin Microbiol Rev (1996) 1.02
Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1. J Virol (1995) 1.02
A rapid procedure for the quantitation of low abundance RNAs by competitive reverse transcription-polymerase chain reaction. Nucleic Acids Res (1994) 1.00
A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes. J Virol (1993) 0.91
Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest (1997) 0.91
An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J Virol (1995) 0.84
Early increase of CD4+ CD45RA+ and CD4+ CD95- cells with conserved repertoire induced by anti-retroviral therapy in HIV-infected patients. Clin Exp Immunol (1998) 0.81
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science (1988) 13.46
The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science (1988) 11.05
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med (1989) 10.74
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Extensive variation of human immunodeficiency virus type-1 in vivo. Nature (1988) 5.02
Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol (1991) 3.94
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro. J Virol (1991) 2.91
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Direct detection of HIV RNA expression in seropositive subjects. Lancet (1988) 2.75
Projections of AIDS morbidity and mortality in San Francisco. JAMA (1990) 2.42
Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol (1992) 1.85
The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med (1991) 1.81
Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. Virology (1990) 1.79
Direct detection of HIV-1 RNA from AIDS and ARC patient samples. DNA (1988) 1.79
Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. AIDS Res Hum Retroviruses (1991) 1.62
Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. J Med Virol (1987) 1.61
Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. J Med Virol (1991) 1.26
Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI). AIDS Res Hum Retroviruses (1990) 1.17
The polymerase chain reaction for the detection of HIV-1 genomic RNA in plasma from infected individuals. J Virol Methods (1991) 1.07
Human immunodeficiency virus isolates from asymptomatic homosexual men and from AIDS patients have distinct biologic and genetic properties. Virology (1991) 0.98
Perinatal infection by human immunodeficiency virus type 1 (HIV-1): relationship between proviral copy number in vivo, viral properties in vitro, and clinical outcome. J Med Virol (1991) 0.92
Detection of human immunodeficiency virus type 1 transcripts in peripheral blood lymphocytes by the polymerase chain reaction. J Virol Methods (1991) 0.86
Human immunodeficiency virus type 1 and hepatitis B virus transcription in peripheral blood lymphocytes from co-infected subjects. Arch Virol (1992) 0.81
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69
A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. Gene (1992) 3.48
Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem (2000) 2.98
Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med (1995) 2.75
Start sites of bidirectional DNA synthesis at the human lamin B2 origin. Science (2000) 2.72
Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob Agents Chemother (1999) 2.52
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin. Antimicrob Agents Chemother (1983) 2.51
Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS (1996) 2.41
Microarray application in prenatal diagnosis: a position statement from the cytogenetics working group of the Italian Society of Human Genetics (SIGU), November 2011. Ultrasound Obstet Gynecol (2012) 2.38
Quantitative PCR and RT-PCR in virology. PCR Methods Appl (1993) 2.20
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG (2012) 2.14
HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci U S A (1998) 2.12
High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology (1999) 2.12
A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med (1991) 2.10
Evaluation of prenatal ultrasound diagnosis of fetal abdominal wall defects by 19 European registries. Ultrasound Obstet Gynecol (2001) 2.10
Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med (1997) 1.92
Bacteriolytic activity in staphylococci. Infect Immun (1977) 1.90
Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. Nucleic Acids Res (1998) 1.86
Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol (1992) 1.85
E2F family members are differentially regulated by reversible acetylation. J Biol Chem (2000) 1.77
Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect (2003) 1.72
A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1. Virology (1992) 1.72
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Epidemiology and microbiology of surgical wound infections. J Clin Microbiol (2000) 1.67
The gene for a novel human lamin maps at a highly transcribed locus of chromosome 19 which replicates at the onset of S-phase. Mol Cell Biol (1992) 1.66
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1999) 1.62
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology (2007) 1.61
Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet (2001) 1.61
Serological follow-up of patients involved in a localized outbreak of leptospirosis. J Clin Microbiol (1991) 1.59
Further characterization of borderline methicillin-resistant Staphylococcus aureus and analysis of penicillin-binding proteins. Antimicrob Agents Chemother (1990) 1.56
Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol (1999) 1.50
Simplified lyogroup system, a new method for routine identification of staphylococci: description and comparison with three other methods. J Clin Microbiol (1980) 1.50
Identification of a SUFU germline mutation in a family with Gorlin syndrome. Am J Med Genet A (2009) 1.49
Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit Care Med (2001) 1.48
Nested polymerase chain reaction for high-sensitivity detection of enteroviral RNA in biological samples. J Clin Microbiol (1993) 1.48
Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet (2005) 1.45
How wide is the clinical spectrum of the acrocallosal syndrome? Report of a mild case. J Med Genet (1990) 1.44
High-resolution mapping of the origin of DNA replication in the hamster dihydrofolate reductase gene domain by competitive PCR. Mol Cell Biol (1996) 1.44
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS (2001) 1.41
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Differentiation of resistance phenotypes among erythromycin-resistant Pneumococci. J Clin Microbiol (2001) 1.40
In vivo footprinting analysis of constitutive and inducible protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1. J Virol (1993) 1.39
Purification and characterization of three separate bacteriolytic enzymes excreted by Staphylococcus aureus, Staphylococcus simulans, and Staphylococcus saprophyticus. J Bacteriol (1982) 1.39
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia (1993) 1.38
Defective intracellular transport and processing of OA1 is a major cause of ocular albinism type 1. Hum Mol Genet (2000) 1.38
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis (1995) 1.37
Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life (2001) 1.37
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother (1997) 1.35
In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin. Antimicrob Agents Chemother (1986) 1.35
SmaI macrorestriction analysis of Italian isolates of erythromycin-resistant Streptococcus pyogenes and correlations with macrolide-resistance phenotypes. Microb Drug Resist (2001) 1.35
A waterborne outbreak of leptospirosis. Am J Epidemiol (1987) 1.35
Human case of autochthonous West Nile virus lineage 2 infection in Italy, September 2011. Euro Surveill (2011) 1.35
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis (2006) 1.34
Standardization of antifungal susceptibility testing and clinical relevance. Med Mycol (1998) 1.33
Cell cycle modulation of protein-DNA interactions at a human replication origin. EMBO J (1998) 1.32
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem (1997) 1.32
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy. Heart (1997) 1.30
Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother (1991) 1.30
Routine separation of staphylococci from micrococci based on bacteriolytic activity production. J Clin Microbiol (1979) 1.29
Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol (2001) 1.29
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother (2000) 1.28
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agents Chemother (1996) 1.28
In vivo protein-DNA interactions at human DNA replication origin. Proc Natl Acad Sci U S A (1996) 1.27
Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol (1996) 1.27
Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. J Med Virol (1991) 1.26
Detection of bacterial phosphatase activity by means of an original and simple test. J Clin Pathol (1979) 1.26
Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet (2004) 1.25
Evaluation of prenatal diagnosis of congenital heart diseases by ultrasound: experience from 20 European registries. Ultrasound Obstet Gynecol (2001) 1.25
C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J Exp Med (1997) 1.24
Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis (2000) 1.24
Comparative evaluation of the MB-Check system for recovery of mycobacteria from clinical specimens. Eur J Clin Microbiol Infect Dis (1992) 1.23
Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.23
Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother (2001) 1.22
Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? Clin Infect Dis (1996) 1.22
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother (1998) 1.22
Identification, clinical distribution, and susceptibility to methicillin and 18 additional antibiotics of clinical Staphylococcus isolates: nationwide investigation in Italy. J Clin Microbiol (1984) 1.21
A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet (1996) 1.21